LY-333328: Glycopeptide Antibiotic

Drugs of the Future

Volumn 23, Issue 1, 1998, Pages 17-23

  Fromtling, Robert A ^a   Castaner J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROORIENTICIN A; ORITAVANCIN; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOMYCIN; VANCOMYCIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL PERITONITIS; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; STREPTOCOCCUS PNEUMONIAE;

EID: 2642684570     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1998.023.01.439603     Document Type: Article

References (43)

1. Cooper, R.D.G., Snyder, N.J., Zweifel, M.J. et al. Reductive alkylation of glycopeptide antibiotics: Synthesis and antibacterial activity. J Antibiot 1996, 49: 575-81.
2. Cooper, R.D.G., Huff, B.E., Nicas, T.I. et al. (Eli Lilly & Co.). Glycopeptide antibiotic derivs. WO 9630401.
3. Cooper, R.D.G., Huff, B.E., Nicas, T.I. et al. (Eli Lilly & Co.). Glycopeptide antibiotic derivs. EP 667353.
4. Lin, Y., Stratford, R.E., Zornes, L.L. et al. Non-clinicalpharmacokinetics of LY333328, a semisynthetic glycopeptide antibiotic active against vancomycin-resistant enterococci. 35th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, San Francisco) 1995, Abst 254.
5. Boylan, C.J., Nicas, T.I., Preston, D.A. et al. Efficacy of semi-synthetic glycopeptides active against vancomycin-resistant enterococci in a mouse infection model. 35th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, San Francisco) 1995, Abst 255.
6. Nagarajan, N. Antibacterial activities and modes of action of vancomycin and related glycopeptides. Antimicrob Agents Chemother 1991, 35: 605-9.
7. Nagarajan, N. Structure-activity relationships of vancomycin-type glycopeptide antibiotics. J Antibiot 1993, 46: 1181-95.
8. Nicas, T.I., Mullen, D.H., Klokowitsch, J.E., Preston, D.A., Snyder, N.J., Stratford, R.A., Cooper, R.D.G. Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other Gram-positive bacteria. Antimicrob Agents Chemother 1995, 39: 2585-7.
9. Nicas, T.I., Mullen, D.H., Flokowitsch, J.E., Preston, D.A., Snyder, N.J., Zweifel, M.J., Wilkie, S.C., Rodriquez, M.J., Thompson, R.C., Cooper, R.D.G. Semisynthetic glycopeptide antibiotics derived from LY264326 active against vancomycin-resistant enterococci. Antimicrob Agents Chemother 1996, 40: 2194-9.
10. Stack, D.R., Letourneau, D.L., Mullen, D.L., Butler, T.F., Allen, N.E., Kline, A.D., Nicas, T.I., Thompson, R.C. Covalent glycopeptide dimers: Synthesis, physical characterization, and antibacterial activity. 37th lntersci Conf Antimicrob Agents Chemother (Sept 28-Oct 1, Toronto) 1997, Abst F1.
11. Snyder, N.J., Zweifel, M.J., Cooper, R.D.G., Rodriquez, M.J., Nicas, T.I., Mullen, D.L., Butler, T.F. New semisynthetic glycopeptide amides active against resistant enterococci. 37th lntersci Conf Antimicrob Agents Chemother (Sept 28-Oct 1, Toronto) 1997, Abst F2.
12. Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993. Morb Mortal Wkly Rep 1993, 42: 597-9.
13. Murray, B.E. Editorial response: What can we do about vancomycin-resistant enterococci? Clin Infect Dis 1995, 20: 1134-6.
14. Uttley, A.H.C., George, R.C., Naidoo, J., Woodford, N., Johnson, A.P., Collins, C.H., Morrison, D., Gilfillan, A.J., Fitch, L.E., Heptonstall, J. High-level vancomycin-resistant enterococci causing hospital infections. Epidemiol Infect 1989, 103: 173-81.
15. Manso, E., De Sio, G., Biavasco, F, Varaldo, P.E., Sambo, G., Maffei, C. Vancomycin-resistant enterococci. Lancet 1993, 342: 615-7.
16. Venditti, M., Biavasco, F., Varaldo, P.E., Macchiarelli, A., De Biase, L., Marino, B., Serra, P. Catheter-related endocarditis due to glycopeptide-resistant Enterococcus faecalis in a transplanted heart. Clin Infect Dis 1993, 17: 524-5.
17. Nicas, T.I., Mullen, D.L., Flokowitsch, J.E., Preston, D.A. Bactericidal activity against enterococci of the semisynthetic glycopeptide LY333328. 36th Intersci Conf Antimicrob Agents Chemother (Sept 15-18, New Orleans) 1996, Abst F198.
18. Felmingham, D., Robbins, M.J. In vitro activity of LY333328, a semi-synthetic glycopeptide active against glycopeptide-resistant enterococci, in various test media. 36th Intersci Conf Antimicrob Agents Chemother (Sept 15-18, New Orleans) 1996, Abst F199.
19. Zelenitsky, S., Karlowsky, J., Hoban, D., Kabani, A., Zechel, M., Zhanel, G. Bactericidal activity of an investigational glycopeptide, LY333328, against vancomycin-sensitive and vancomycin-resistant Enterococcus faecium. 36th Intersci Conf Antimicrob Agents Chemother (Sept 15-18 New Orleans) 1996, Abst F200.
20. Baltch, A.L., Smith, R.P., Ritz, W. Inhibitory/bactericidal activity of LY333328 against vancomycin-resistant Enterococcus faecium (VRE). 36th Intersci Conf Antimicrob Agents Chemother (Sept 15-18, New Orleans) 1996, Abst F201.
21. Biavasco, F., Lupidi, R., Manso, E., Vignaroli, C., Facinelli, B., Varaldo, P.E. In vitro activity of LY333328 against Gram-positive bacteria resistant or moderately susceptible to clinically available glycopeptides (GPs). 36th Intersci Conf Antimicrob Agents Chemother (Sept 15-18, New Orleans) 1996, Abst F202.
22. Barrett, M.S., Erwin, M.E., Jones, R.N. Antimicrobial activity of a new glycopeptide derivative, LY333328, tested against resistant Gram-positive organisms. 36th Intersci Conf Antimicrob Agents Chemother (Sept 15-18, New Orleans) 1996, Abst F203.
23. Donabedian, S., Perri, M.B., Thal, L.A., Zervos, M.J. Comparative in vitro and bactericidal activity of LY333328 against multi-drug resistant enterococci. 36th Intersci Conf Antimicrob Agents Chemother (Sept 15-18, New Orleans) 1996, Abst F204.
24. Rouse, M.S., Piper, K.E., Patel, R., Cockerill, F.R., Wilson, W.R., Steckelberg, J.M. In vitro activity of LY333328 against vancomycin resistant (vanA, vanB, vanC1, vanC2) enterococci. 36th Intersci Conf Antimicrob Agents Chemother (Sept 15-18, New Orleans) 1996, Abst F205.
25. Mercier, M.C., Houlihan, H.H., Rybak, M.J. In vitro activity of a new glycopeptide, LY333328 (LY), alone and in combination with vancomycin (V), rifampicin (R), and gentamicin (G) against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VREF) at standard (SI) and high inoculum (HI). 36th Intersci Conf Antimicrob Agents Chemother (Sept 15-18, New Orleans) 1996, Abst F206.
26. Anzak, A., Mercier, R.C., Rybak, M.J. In vitro activity of investigational antibiotics alone and in combinations against two strains of vancomycin-resistant Enterococcus faecium (VREF). 36th Intersci Conf Antimicrob Agents Chemother (Sept 15-18, New Orleans) 1996, Abst F207.
27. Fasola, E.L., Spangler, S.K., Ednie, L.M., Bajaksouzian, S., Jacobs, J., Appelbaum, P.C. Antipneumococcal activity of LY333328, a new glycopeptide. 36th Intersci Conf Antimicrob Agents Chemother (Sept 15-18, New Orleans) 1996, Abst F208.
28. Mercier, R.B., Rybak, M.J. Effect of protein and concentration on the pharmacodynamic properties of a new glycopeptide, LY333328 (LY). 36th Intersci Conf Antimicrob Agents Chemother (Sept 15-18, New Orleans) 1996, Abst F209.
29. Muller-Serieys, C., Vallee, E., Pangon, B., Chachaty, E., Decre, D. In vitro activity of LY333328, a new glycopeptide, against Gram-positive cocci. 37th Intersci Conf Antimicrob Agents Chemother (Sept 28-Oct 1, Toronto) 1997, Abst F3.
30. Mir, N., Baquero, F., Sanchez, M., Luque, R., Lopez, B., Canton, R. Comparative in vitro activity and inoculum effect of LY333328 against vancomycin resistant and susceptible enterococci isolates obtained from ICU patients. 37th Intersci Conf Antimicrob Agents Chemother (Sept 28-Oct 1, Toronto) 1997, Abst F4.
31. Garcia-Garrote, F., Alcala, L., Cercenado, E., Bouza, E. In vitro activity of the new glycopeptide LY333328 against Gram-positive clinical isolates. 37th Intersci Conf Antimicrob Agents Chemother (Sept 28-Oct 1, Toronto) 1997, Abst F5.
32. Sloos, J.H., Van de Klunert, J.A.M., Seymonson, W.G., Van Boven, C.P.A. Susceptibility of coagulase-negative staphylococci to a new glycopeptide (LY333328). 37th Intersci Conf Antimicrob Agents Chemother (Sept 28-Oct 1, Toronto) 1997, Abst F6.
33. Hoban, D., Cox, L., Palatnick, L., Weshnoweski, B., Kabani, A., Zelenitsky, S., Karlowsky, J., Zhanel, G. Comparative in vitro activity of LY333328, a new glycopeptide, against Enterococcus gallinarum and Enterococcus casseliflavus. 37th Intersci Conf Antimicrob Agents Chemother (Sept 28-Oct 1, Toronto) 1997, Abst F7.
34. Cheron, M., Boisivon, A. In vitro bactericidal effect of LY333328 against vancomycin resistant and susceptible E. faecium. 37th Intersci Conf Antimicrob Agents Chemother (Sept 28-Oct 1, Toronto) 1997, Abst F8.
35. Zelenitsky, S., Booker, B., Karlowsky, J., Hoban, D., Laing, N., Kabani, A., Zeckel, M., Zhanel, G. Synergistic activity of an investigational glycopeptide, LY333328, and once-daily gentamicin against vancomycin-resistant Enterococcus faecium (VRE) in a multiple dose in vitro pharmacodynamic model. 37th Intersci Conf Antimicrob Agents Chemother (Sept 28-Oct 1, Toronto) 1997, Abst F9.
36. Bauernfeind, A., Eberlein, E., Jungwirth, R. Bactericidal effect of LY333328 against staphylococci and enterococci in a pharmacodynamic model. 37th Intersci Conf Antimicrob Agents Chemother (Sept 28-Oct 1, Toronto) 1997, Abst F14.
37. Zhanel, G., Kirkpatrick, I., Zelenitsky, S., Karlowsky, J., Kabani, A., Hoban, D. The influence of human serum on pharmacodynamic properties of an investigational glycopeptide LY333328, teicoplanin and comparator agents against S. aureus. 37th lntersci Conf Antimicrob Agents Chemother (Sept 28-Oct 1, Toronto) 1997, Abst F15.
38. Novelli, A., Mazzei, T., Fallani, S., Cassetta, M.I., Conti, S. In vitro postantibiotic effect of the semisynthetic glycopeptide LY333328 on clinical Gram-positive pathogens. 37th Intersci Conf Antimicrob Agents Chemother (Sept 28-Oct 1, Toronto) 1997, Abst F16.
39. Kundsen, J.D., Raber, S., Leggett, J., Fuursted, K., Espersen, F., Frimodt-Moller, N. Comparison of effect of LY333328 with teicoplanin and vancomycin against pneumococci in the mouse peritonitis model. 37th Intersci Conf Antimicrob Agents Chemother (Sept 28-Oct 1, Toronto) 1997, Abst F10.
40. Kaatz, G.W., Seo, S.M., Aeschlimann, J.R., Houlihan, H.H., Mercier, R.C., Rybak, M.J. Comparative efficacy of LY333328 [L] and vancomycin [V] in the therapy of experimental methicillin-resistant Staphylococcus aureus [MRSA] endocarditis in rabbits. 37th Intersci Conf Antimicrob Agents Chemother (Sept 28-Oct 1, Toronto) 1997, Abst F11.
41. Saleh-Mghir, A., Lefort, A., Petegniff, Y., Vallois, J.M., Le Guludec, D., Fantin, B., Carbon, C. Activity and diffusion of LY333328 in experimental endocarditis due to Enterococcus faecalis. 37th Intersci Conf Antimicrob Agents Chemother (Sept 28-Oct 1, Toronto) 1997, Abst F12.
42. Schwalbe, R.S., Iarocci, T.R. Establishment of a neutropenic mouse model to characterize activity of LY333328 against vancomycin-resistant enterococci. 37th Intersci Conf Antimicrob Agents Chemother (Sept 28-Oct 1, Toronto) 1997, Abst F13.
43. Biavasco, F., Vignaroli, C., Lupidi, R., Manso, E., Facinelli, B., Varaldo, P.E. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide. Antimicrob Agents Chemother 1997, 41: 2165-72.